Study of riociguat for pulmonary hypertension on triple therapy
Part of Lungs & breathing clinical trials.
This trial tests switching from one blood vessel relaxer (a PDE-5i) to another (riociguat) for people with pulmonary arterial hypertension who are already on three medications. It looks at how this switch affects their condition over 6 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have been diagnosed with pulmonary arterial hypertension (Group 1 PAH)
- You have been on triple therapy (including an endothelin receptor antagonist, a prostacyclin pathway agent, and a PDE-5i) for at least 12 weeks
- Your doctor plans to switch you from a PDE-5i to riociguat as part of your regular care
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking injected treprostinil together with riociguat can improve how the heart and lung blood vessels work in people with advanced pulmonary artery hypertension (PAH). It may help improve blood-flow measurements and the structure of the heart.
This trial tests an investigational drug called NS-863 for people with pulmonary arterial hypertension (PAH). It aims to see if it can improve exercise ability and symptoms when added to your current PAH therapy.
This trial tests an inhaled medication (TPIP) that opens blood vessels in the lungs to help you breathe easier and be more active. It is for people with PAH who are already on stable treatment and have moderate symptoms.
This study compares starting treatment with three medicines, including a continuous infusion (treprostinil), versus two oral medicines for people newly diagnosed with moderate-to-high risk pulmonary arterial hypertension (PAH). The goal is to see which approach improves heart function and symptoms more effectively.
This trial tests switching from sildenafil to a newer medicine called riociguat for people with CTEPH (a type of lung blood pressure problem) who still have symptoms after a balloon procedure. The goal is to see if the switch helps them feel better.
This trial is for people with a type of long-term blood clot in the lungs (CTEPH) who have been taking riociguat for at least 12 weeks. It will see what happens when the medication is stopped, focusing on how the right side of the heart is doing.
Hear when a new Pulmonary Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.